Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Up – Should You Buy?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s share price gapped up prior to trading on Tuesday. The stock had previously closed at $27.14, but opened at $28.48. Kestra Medical Technologies shares last traded at $28.2890, with a volume of 17,180 shares.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on KMTS shares. Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. BTIG Research reaffirmed a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Finally, Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.38.

Kestra Medical Technologies Price Performance

The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The stock has a fifty day simple moving average of $25.32 and a two-hundred day simple moving average of $22.82. The company has a market cap of $1.69 billion, a PE ratio of -10.59 and a beta of 0.62.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%.The business had revenue of $30.97 million for the quarter. On average, equities analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Elizabeth Kwo sold 4,010 shares of the company’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $24.26, for a total transaction of $97,282.60. Following the transaction, the director directly owned 14,116 shares of the company’s stock, valued at $342,454.16. This represents a 22.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mary Ladone sold 3,908 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $25.20, for a total transaction of $98,481.60. Following the completion of the sale, the director owned 37,507 shares of the company’s stock, valued at $945,176.40. This trade represents a 9.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 243,598 shares of company stock valued at $5,899,971 in the last quarter. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KMTS. Brown Advisory Inc. lifted its position in shares of Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after acquiring an additional 428,996 shares during the period. Eventide Asset Management LLC grew its holdings in shares of Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares during the period. Next Century Growth Investors LLC increased its stake in Kestra Medical Technologies by 154.5% in the 4th quarter. Next Century Growth Investors LLC now owns 465,845 shares of the company’s stock valued at $12,354,000 after purchasing an additional 282,832 shares in the last quarter. Summit Partners Public Asset Management LLC acquired a new position in Kestra Medical Technologies during the fourth quarter worth $9,282,000. Finally, Sei Investments Co. boosted its position in Kestra Medical Technologies by 22.6% during the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after purchasing an additional 43,753 shares in the last quarter.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.